Gene Mack, CEO, GAIN Therapeutics, highlights early Phase Ib data showing GT-02287 may enhance neuroprotection across a wider spectrum of Parkinson’s patients regardless of genetic status.

Q2 2025 Management View CEO Jon R. Cohen reported "meaningful progress on several initiatives across the business and added a ...

Tariffs— Shawn Munsell stated, "Under the 10% tariff environment, our exposure without mitigation could approach $8 million ...

Guidance remains unchanged, with management projecting "over $100 million in partnership inflows by the end of 2026" and targeting a cash burn below $390 million in 2026. The company anticipates a ...

Furthermore, the Company has been provided an update that its first orders of twenty (20) ElphaPex DG1+ miners are scheduled ...

Discover New Mountain Finance Corporation's Q2 2025 earnings insights, including a stable $0.32 dividend, portfolio updates, refinancing plans, ...

How leading retailers use search intelligence to navigate AI overviews, optimize shopping ads, and win market share.

ADM topped Q2 EPS expectations despite softer sales and segment profits, narrowed full-year guidance, and sees biofuel policy ...

Backlog -- Backlog reached a record of nearly $23 billion in Q3 fiscal 2025, up 14% year-over-year; Trailing twelve-month ...

Fox’s broadcast TV division earned $1.71 billion in revenue during Q4, fueled primarily by a healthy mix of advertising and ...

Fox saw its advertising revenue up 7 per cent in its Q4, with the corporation saying the growth was driven by Tubi, its free ...

NVIDIA continues to fuel the AI stock rally in 2024. Our analysis shows that may be the case for the foreseeable future.